Clinical trials: Food Allergy Peanut
Peanut Allergy
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
Severe peanut allergy is different from other allergic reactions because it can lead to fatal reactions and is an invisible disability. There is no cure today.
- Trial name
- FASTX (NCT02402231)
- Testing
- Omalizumab
- Where
- Sweden
- Volunteers
- 23 people
- Sponsor
- Caroline Nilsson
Food Allergy in Infants
Early Allergen System Experience
Multiple clinical trials have demonstrated that early allergen introduction, feeding babies common food allergens before six months, decreases children's risk of developing a food allergy.
- Trial name
- EASE (NCT06262867)
- Testing
- Ready. Set. Food! Stage 1 Mix ins
- Where
- United States
- Volunteers
- 1,110 people, healthy volunteers welcome
- Sponsor
- Prollergy dba Ready Set Food
Peanut Hypersensitivity
Oral Peanut Immunotherapy for Peanut Allergic Patients
This is a study to determine if peanut oral immunotherapy (OIT) would desensitize or tolerize peanut allergic patients to peanuts in order prevent peanut allergic reactions.
- Trial name
- PnOIT (NCT01891136)
- Testing
- Peanut protein
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of North Carolina, Chapel Hill
Food Allergy Peanut, Food Allergy in Infants
Intervention to Reduce Early (Peanut) Allergy in Children
iREACH is a five-year NIH funded study aimed at assessing and improving pediatric clinician adherence to the 2017 NIAID Prevention of Peanut Allergy (PPA) Guidelines.
- Trial name
- iREACH (NCT04604431)
- Testing
- iREACH CDS Tool
- Where
- 30 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Peanut Allergy
Identification of Anaphylactogenic Antibodies in Peanut Allergy
This project intends the analysis and profiling of specific antibodies against major peanut allergens in peanut allergic individuals and molecular cloning of human antibodies against major peanut allergens.
- Trial name
- NCT02821286
- Testing
- Observational study
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Allergy, Peanut, Peanut Allergy
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
This is a phase II trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients.
- Conditions
- Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis
- Trial name
- NCT05695261
- Testing
- Microbial Transplantation Therapy, Antibiotic, Oral Immunotherapy (OIT)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rima Rachid
Peanut Allergy
A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects
The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.
- Trial name
- V712-103 (NCT03352726)
- Testing
- DBV712 IHRP
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- DBV Technologies
Peanut Allergy, Milk Allergy
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Food allergy is on the rise within the pediatric population. Having food allergy can cause medical, nutritional and psychological issues in those who suffer with it.
- Conditions
- Peanut Allergy, Milk Allergy, Egg Allergy
- Trial name
- IMMULITE 2000 (NCT01950533)
- Testing
- Oral food challenge
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Jewish Health
Peanut Allergy
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
In this trial the investigators aim to assess the effectiveness and safety of oral immunotherapy with peanut protein in high and low dose (300mg versus 150mg) in children with peanuts allergy.
- Trial name
- NCT04415593
- Testing
- High dose of peanuts, Low dose of peanuts
- Where
- Poland
- Volunteers
- 44 people
- Sponsor
- Medical University of Warsaw
Peanut Allergy
Clinical and Biological Efficacy of Peanut Oral Immunotherapy
An oral tolerance induction (OTI) protocol is conducted at the allergy Unit of Saint Vincent Hospital of Lille (France) in standard care since 2006.
- Trial name
- NCT02979600
- Volunteers
- 493 people
- Sponsor
- Lille Catholic University
Peanut Allergy
Safety of MOON101 for the Treatment of Peanut Allergy
The goal of this open-label, single escalating dose study in 3 sequential groups: adults, adolescents, and children with peanut allergy is to assess the safety of MOON101. The main question it aims to answer is: 1.
- Trial name
- SURVEYOR (NCT07580898)
- Testing
- Dose A, Dose B, Dose C
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Moonlight Therapeutics, Inc.
Food Allergy, Peanut Allergy
Omalizumab in the Treatment of Peanut Allergy
The purpose of this study is to determine if treatment with omalizumab (Xolair, anti-IgE) can eliminate or reduce symptoms of peanut allergy.
- Trial name
- NCT00949078
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Johns Hopkins University
Peanut Hypersensitivity
Peanut Oral Immunotherapy in Children
This is a randomized, double-blind, placebo-controlled, multi-center study comparing peanut oral immunotherapy (OIT) to placebo in the induction of tolerance and desensitization in peanut-allergic children.
- Trial name
- IMPACT (NCT01867671)
- Testing
- Peanut Oral Immunotherapy - Liquid Extract, Peanut Oral Immunotherapy - Peanut Flour
- Where
- 5 sites in United States
- Volunteers
- 146 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Food Allergy in Children, Oral Immunotherapy for Food Allergy
A Randomized Controlled Trial of Oral Immunotherapy Versus Allergen Avoidance in Children Under 2 Years With Food Allergy
The goal of this clinical trial is to learn whether oral immunotherapy (OIT) is safe and effective for treating food allergy in children aged 0-2 years with peanut, tree nut, or sesame allergy.
- Trial name
- SAFARI (NCT07825662)
- Testing
- Oral immunotheraphy (OIT)
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- Copenhagen Studies on Asthma in Childhood
Peanut Allergy
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)
- Trial name
- NCT07117669
- Testing
- ENP-501
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- N-Fold, LLC
Allergy Testing, Peanut Allergies
BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)
The goal of this exploratory pilot study is to generate early data needed for future validation studies of the automated BÜHLMANN BAT (Basophil activation test) assay.
- Conditions
- Allergy Testing, Peanut Allergies, Venom Allergy, House Dust Mite Allergy
- Trial name
- NCT07596303
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Bühlmann Laboratories AG
Peanut Allergy
Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults
The goal of this study is to produce a new treatment that would benefit adult subjects by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut…
- Trial name
- NCT01274429
- Testing
- Peanut flour
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Hypersensitivity
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
The purpose of this study is to determine whether the addition of anti-IgE treatment will make peanut oral immunotherapy safer, more tolerable, and more effective in treating peanut allergy.
- Trial name
- PAIE/Xolair (NCT00932282)
- Testing
- Peanut Oral Immunotherapy, Omalizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Viaskin® Peanut (DBV712) Expanded Access Protocol
This is an open label expanded access program for male and female patients ≥ 4 years old.
- Trial name
- NCT04371627
- Testing
- Viaskin Peanut
- Sponsor
- DBV Technologies
Food Allergy, Peanut Allergy
Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children.
This protocol will help better define whether patients with peanut and/or tree nut food allergy can tolerate traces in products with precautionary allergen labelling.
- Conditions
- Food Allergy, Peanut Allergy, Tree Nut Allergy
- Trial name
- NCT03680066
- Testing
- Oral food challenge to foods with traces
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva